Transcriptional control of leukemogenesis by the chromatin reader SGF29
Karina Barbosa, Anagha Deshpande, Marlenne Perales, Ping Xiang, Rabi Murad, Akula Bala Pramod, Anna Minkina, Neil Robertson, Fiorella Schischlik, Xue Lei, Younguk Sun, Adam Brown, Diana Amend, Irmela Jeremias, John G. Doench, R. Keith Humphries, Eytan Ruppin, Jay Shendure, Prashant Mali, Peter D. Adams, Aniruddha J. Deshpande
Abstract
ABSTRACT: Aberrant expression of stem cell-associated genes is a common feature in acute myeloid leukemia (AML) and is linked to leukemic self-renewal and therapy resistance. Using AF10-rearranged leukemia as a prototypical example of the recurrently activated "stemness" network in AML, we screened for chromatin regulators that sustain its expression. We deployed a CRISPR-Cas9 screen with a bespoke domain-focused library and identified several novel chromatin-modifying complexes as regulators of the TALE domain transcription factor MEIS1, a key leukemia stem cell (LSC)-associated gene. CRISPR droplet sequencing revealed that many of these MEIS1 regulators coordinately controlled the transcription of several AML oncogenes. In particular, we identified a novel role for the Tudor-domain-containing chromatin reader protein SGF29 in the transcription of AML oncogenes. Furthermore, SGF29 deletion impaired leukemogenesis in models representative of multiple AML subtypes in multiple AML subtype models. Our studies reveal a novel role for SGF29 as a nononcogenic dependency in AML and identify the SGF29 Tudor domain as an attractive target for drug discovery.